Modulating Tumor-Associated Macrophage Polarization by Synthetic and Natural PPARγ Ligands as a Potential Target in Breast Cancer.
Breast Neoplasms
/ drug therapy
Cell Differentiation
/ drug effects
Cell Line
Cell Polarity
/ drug effects
Culture Media, Conditioned
/ pharmacology
Cytokines
/ metabolism
Docosahexaenoic Acids
/ pharmacology
Ethanolamines
/ pharmacology
Female
Humans
Ligands
Molecular Targeted Therapy
Monocytes
/ drug effects
PPAR gamma
/ metabolism
Rosiglitazone
/ pharmacology
Tumor-Associated Macrophages
/ drug effects
breast tumor microenvironment
docosahexaenoyl ethanolamine (DHEA)
docosahexaenoyl serotonin (DHA-5-HT)
n-3 polyunsaturated fatty acids
peroxisome proliferator-activated receptor gamma
rosiglitazone
tumor associated macrophages
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
10 01 2020
10 01 2020
Historique:
received:
18
09
2019
revised:
13
12
2019
accepted:
08
01
2020
entrez:
16
1
2020
pubmed:
16
1
2020
medline:
16
1
2021
Statut:
epublish
Résumé
Activation of peroxisome proliferator-activated receptor gamma (PPARγ) elicits anti-proliferative effects on different tumor cells, including those derived from breast cancer. PPARγ is also expressed in several cells of the breast tumor microenvironment, among which tumor associated macrophages (TAMs) play a pivotal role in tumor progression and metastasis. We explored the ability of synthetic and natural PPARγ ligands to modulate TAM polarization. The ligands included rosiglitazone (BRL-49653), and two docosahexaenoic acid (DHA) conjugates,
Identifiants
pubmed: 31936729
pii: cells9010174
doi: 10.3390/cells9010174
pmc: PMC7017381
pii:
doi:
Substances chimiques
Culture Media, Conditioned
0
Cytokines
0
Ethanolamines
0
Ligands
0
PPAR gamma
0
synaptamide
0
Rosiglitazone
05V02F2KDG
Docosahexaenoic Acids
25167-62-8
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Nat Rev Clin Oncol. 2017 Jul;14(7):399-416
pubmed: 28117416
J Natl Cancer Inst. 1995 Apr 19;87(8):587-92
pubmed: 7752256
Cancer Res. 2011 Apr 1;71(7):2455-65
pubmed: 21459803
Biochim Biophys Acta. 2010 Oct;1801(10):1107-14
pubmed: 20601112
Am J Clin Nutr. 2010 May;91(5):1294-302
pubmed: 20219961
Int J Cancer. 2009 Feb 15;124(4):924-31
pubmed: 19035453
Endocr Relat Cancer. 2008 Jun;15(2):545-57
pubmed: 18509005
Cardiovasc Diabetol. 2008 Mar 20;7:6
pubmed: 18355413
Cell. 2010 Apr 2;141(1):39-51
pubmed: 20371344
J Clin Oncol. 2006 Jul 20;24(21):3401-7
pubmed: 16849754
Br J Nutr. 2012 Jun;107 Suppl 2:S228-39
pubmed: 22591896
Prostaglandins Leukot Essent Fatty Acids. 2011 Dec;85(6):305-10
pubmed: 21995886
J Immunother Cancer. 2019 May 28;7(1):140
pubmed: 31138333
J Leukoc Biol. 2002 Mar;71(3):388-400
pubmed: 11867676
Cell Metab. 2007 Aug;6(2):137-43
pubmed: 17681149
Br J Nutr. 2011 Jun 28;105(12):1798-807
pubmed: 21294934
Nutrients. 2019 Apr 24;11(4):
pubmed: 31022842
Endocr Rev. 1999 Oct;20(5):649-88
pubmed: 10529898
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Int J Mol Sci. 2019 Aug 30;20(17):
pubmed: 31480368
Br J Pharmacol. 2015 Jan;172(1):24-37
pubmed: 24780080
Br J Cancer. 2009 Mar 10;100(5):713-22
pubmed: 19259092
Prostaglandins Other Lipid Mediat. 2019 Oct;144:106351
pubmed: 31260750
Nat Med. 2004 Aug;10(8):789-99
pubmed: 15286780
Trends Immunol. 2015 Apr;36(4):229-39
pubmed: 25770924
Int Immunopharmacol. 2014 Nov;23(1):37-45
pubmed: 25130606
Oncogene. 2013 Dec 5;32(49):5512-21
pubmed: 23770845
Curr Opin Clin Nutr Metab Care. 2012 May;15(3):246-51
pubmed: 22366922
Proc Natl Acad Sci U S A. 2001 May 22;98(11):6402-6
pubmed: 11353819
Biochim Biophys Acta Mol Cell Biol Lipids. 2017 Sep;1862(9):823-831
pubmed: 28526351
Nature. 1998 Jan 1;391(6662):79-82
pubmed: 9422508
PLoS One. 2010 Apr 22;5(4):e10296
pubmed: 20421971
Cancer Epidemiol Biomarkers Prev. 2001 Jan;10(1):3-8
pubmed: 11205486
Cancer Res. 2016 Nov 15;76(22):6439-6442
pubmed: 28148676
Nutrients. 2014 Oct 30;6(11):4760-93
pubmed: 25360510
Nature. 1998 Jan 1;391(6662):82-6
pubmed: 9422509
Comp Immunol Microbiol Infect Dis. 2019 Dec;67:101355
pubmed: 31586851
Mutat Res. 1999 Jul 15;443(1-2):111-27
pubmed: 10415435
Am J Pathol. 2011 Aug;179(2):1030-40
pubmed: 21704006
Biochim Biophys Acta. 2015 Nov;1850(11):2185-95
pubmed: 26272430
ACS Chem Neurosci. 2017 Mar 15;8(3):548-557
pubmed: 28292183
Br J Pharmacol. 2013 Jun;169(4):772-83
pubmed: 23088259
Am J Clin Nutr. 2009 Aug;90(2):415-24
pubmed: 19515734
Prostaglandins Other Lipid Mediat. 2019 Aug;143:106337
pubmed: 31085370
Cancer Cell. 2005 Mar;7(3):211-7
pubmed: 15766659
Mol Cancer Res. 2012 Jun;10(6):727-38
pubmed: 22532586
Biochim Biophys Acta. 2011 Oct;1811(10):578-86
pubmed: 21798367
JAMA. 2006 Jan 25;295(4):403-15
pubmed: 16434631
BMC Med. 2012 May 21;10:50
pubmed: 22613931
Neoplasia. 2009 Oct;11(10):987-1002
pubmed: 19794958
Breast Cancer Res Treat. 2009 Feb;113(3):423-34
pubmed: 18293083
Cell Cycle. 2011 Jul 15;10(14):2344-54
pubmed: 21654191
Biochim Biophys Acta. 2016 Dec;1861(12 Pt A):2020-2028
pubmed: 27663185
Elife. 2016 Oct 03;5:
pubmed: 27692066
Genes Dev. 2006 Dec 1;20(23):3215-31
pubmed: 17158741
Oncogene. 2015 Jul;34(27):3504-13
pubmed: 25220417
Onco Targets Ther. 2014 Aug 21;7:1475-80
pubmed: 25187727
Br J Cancer. 2008 Dec 16;99(12):2029-36
pubmed: 19018259
J Clin Invest. 2012 Mar;122(3):787-95
pubmed: 22378047
Cell Cycle. 2014;13(4):553-64
pubmed: 24335340
J Investig Med. 2008 Feb;56(2):522-7
pubmed: 18317435
Nature. 1999 Jul 22;400(6742):378-82
pubmed: 10432118
J Cell Mol Med. 2015 May;19(5):1122-32
pubmed: 25721149
Adv Drug Deliv Rev. 2017 May 15;114:206-221
pubmed: 28449873
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancer Res. 2011 Jan 15;71(2):614-24
pubmed: 21224357
Biochim Biophys Acta. 2008 Apr;1781(4):200-12
pubmed: 18316044
Carcinogenesis. 2010 Sep;31(9):1584-91
pubmed: 20660502
Nature. 1970 Nov 14;228(5272):620-2
pubmed: 5529055
J Cell Physiol. 2013 Jun;228(6):1314-22
pubmed: 23168911
Front Immunol. 2019 Jul 31;10:1799
pubmed: 31417566
Immunity. 2004 Feb;20(2):205-18
pubmed: 14975242